Skip to main content

Prognostic Nutritional Index Calculator

Prognostic Nutritional Index (PNI)

Understanding Prognostic Nutritional Index

The Prognostic Nutritional Index (PNI) is a valuable biomarker that combines serum albumin levels and lymphocyte counts to assess both nutritional and immunological status. Originally developed by Onodera et al., this simple but powerful tool has emerged as an important predictor of survival outcomes, particularly in cancer patients.

What is the Prognostic Nutritional Index?

The PNI is calculated using the formula:

PNI = 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm³)

This formula integrates two key components:

  • Serum albumin: A marker of nutritional status and inflammation
  • Total lymphocyte count: Reflects immune system function and response

Normal PNI Values

The optimal PNI cutoff value for predicting outcomes in prostate carcinoma is approximately 49.75, with:

  • Good prognosis: ≥ 49.75
  • Poor prognosis: < 49.75

Clinical Significance

Low PNI (< 49.75)

Associated with:

  • Reduced overall survival
  • Poorer cancer-specific survival
  • Higher disease burden
  • Advanced metastatic disease
  • Compromised nutritional and immune status

Factors Affecting PNI

Albumin levels reflect

  • Nutritional state
  • Inflammatory response
  • Liver function
  • Disease severity
  • Treatment effects

Lymphocyte count indicates

  • Immune system competence
  • Anti-tumor response
  • Inflammatory state
  • Treatment-related effects
  • Disease progression

Clinical Applications

PNI serves as:

  • An independent prognostic marker
  • A predictor of survival outcomes
  • A tool for risk stratification
  • A guide for treatment planning
  • An indicator for nutritional intervention

Calculate PNI now to better understand prognosis and guide clinical decision-making!

References:

  1. Ellez HI, Keskinkilic M, Semiz HS, Arayici ME, Kısa E, Oztop I. The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma. J Clin Med. 2023;12(17):5434.